IBEX Limited - Common Share (IBEX)

On our desk, IBEX's recent Q3 2026 earnings print caught everyone by surprise with a 16.5% stock jump following a strong EPS beat of $0.91 versus the $0.87 consensus. However, looking at the 13F filings from Q1 2026, we noticed a minor selling streak where hedge funds slightly trimmed positions down from absolute peaks. We are advising clients to watch whether institutional accumulation returns before chasing the $38 analyst price target.

From a bio-analyst and specialized professional services viewpoint, the acceleration in health tech is the golden goose here. Top 10 client revenues growing over 25% on average over the past five quarters validates that their end-to-end customer engagement technology solutions are gaining deep enterprise traction. The market reaction (+15.6% following Q3 earnings) proves that execution in high-margin verticals is finally being re-rated by the street.

Watching the 50-day moving average and volume profile on our trading desk, the integration of AI technology and the nearly 54% expansion in the health tech vertical are the primary narrative drivers. When analyzing BPO providers, client retention is everything; IBEX reporting 100% client retention for the quarter and 99.9% annual revenue retention completely alters the traditional churn-heavy narrative of the sector.

As a risk manager reviewing the capital structure, the complete lack of reported debt-to-equity metrics alongside a robust TTM ROE of 30.3% makes IBEX look remarkably efficient operationally. With a trailing P/E of 15.2 and a market cap sitting around $479 million, the current valuation at $35.67 gives us a comfortable cushion relative to its 52-week range of $26 to $43, provided top-line growth sustains its double-digit trajectory.

As a quant researcher tracking institutional smart money signals, 165 hedge funds holding IBEX puts ownership near 96% of its three-year max. While a one-quarter reduction in net flow suggests some profit-taking by early participants, the concentration remains exceptionally high. This level of institutional sponsorship typically creates strong price floors during broader market drawdowns.